Roche’s pipeline trim claims Poseida’s off-the-shelf CAR T asset

Aside from RG6540, Roche also discontinued a host of other early-stage assets, including an antisense oligonucleotide for Alzheimer’s disease and a small-molecule candidate for geographic atrophy.